# Contact RxTA1: Thymosin Alpha-1 Editorial Desk

> Contact RxTA1, an independent Thymosin Alpha-1 research digest. Editorial questions and corrections only — we provide no medical advice and sell no product.

For editorial questions, corrections, and source suggestions about our Thymosin Alpha-1 coverage.

## Get in touch

RxTA1 is an independent editorial digest of the **Thymosin Alpha-1** research literature. If you've spotted an error, have a peer-reviewed source we should cover, or want to flag a study we've missed, the form below reaches the editorial desk. Accuracy matters to us — this compound is widely misreported, and we'd rather fix a mistake than leave it standing.

Please note what we can and can't help with, below, before you write.

## What we can and can't help with

**We can help with:** corrections to our summaries, suggestions for peer-reviewed studies to add, questions about how we read a particular finding, and notes on clarity or accuracy.

**We can't help with:** medical advice, dosing guidance, or treatment decisions — we are not clinicians, and nothing here is a recommendation. We also can't help you buy, source, or obtain the peptide: we don't sell it, don't supply it, and don't refer to vendors. For anything health-related, please consult a qualified clinician who knows your situation. Thymosin Alpha-1 is not FDA-approved in the United States, and questions about its appropriateness for any individual are medical questions, not editorial ones.

---

A bright, plainly-cited read of the Thymosin Alpha-1 record — the immune-peptide signals lit up, the strongest trial's null result kept right in frame, and the look-alike molecules pulled apart; no clinic behind the masthead and nothing here dosed, prescribed, or sold.